MediciNova Announces Positive Clinical Results From MN-166 Phase ...
PipelineReview.com (press release) - Barcelona,Spain
The time to first relapse was also significantly increased in patients treated with 60 mg of MN-166 per day compared to placebo (p=0.04). ...
See all stories on this topic

Equity Futures Dip Ahead of Consumer Confidence Report [delayed]
Insurance News Net - Harrisburg,PA,USA
MNOV: MedicNova reported positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate ...
See all stories on this topic

A Deluge of Drug News
Schaeffers Research - Cincinnati,OH,USA
Meanwhile, MediciNova (MNOV: sentiment , chart, options) stated that the clinical findings from a Phase II clinical trial of MN-166 in multiple sclerosis ...
See all stories on this topic

Pre-Market Stock News (MAR 27, 2007)
24/7 Wall St. - New York,NY,USA
(MNOV) MediciNova announces positive clinical results from MN-166 Phase II multiple sclerosis trial. (MSFT) Microsoft ended up selling 20 million Vista ...
See all stories on this topic

MediciNova MS Phase II: Missed Endpoint, But Hope Remaining
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
MediciNova is talking with advisors to figure out the next steps toward Phase III trials after its MN-166 garnered mostly positive results in a Phase II ...
See all stories on this topic